23.62 USD
+0.68 (+2.96%)
23.63 USD
+0.01 (+0.04%)
Overall CPRX gets a fundamental rating of 8 out of 10. We evaluated CPRX against 531 industry peers in the Biotechnology industry. CPRX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. These ratings could make CPRX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year CPRX was profitable.
CPRX had a positive operating cash flow in the past year.
CPRX had positive earnings in each of the past 5 years.
Each year in the past 5 years CPRX had a positive operating cash flow.
1.2 Ratios
The Return On Assets of CPRX (20.69%) is better than 96.99% of its industry peers.
CPRX has a better Return On Equity (23.65%) than 96.80% of its industry peers.
CPRX's Return On Invested Capital of 21.23% is amongst the best of the industry. CPRX outperforms 97.93% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CPRX is above the industry average of 18.22%.
The last Return On Invested Capital (21.23%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
CPRX has a Profit Margin of 37.64%. This is amongst the best in the industry. CPRX outperforms 96.61% of its industry peers.
In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
CPRX has a better Operating Margin (44.78%) than 99.25% of its industry peers.
CPRX's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 85.68%, CPRX belongs to the best of the industry, outperforming 88.32% of the companies in the same industry.
In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CPRX is creating value.
CPRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CPRX has been increased compared to 5 years ago.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CPRX has an Altman-Z score of 15.66. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 15.66, CPRX belongs to the best of the industry, outperforming 86.25% of the companies in the same industry.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.66 |
ROIC/WACC2.42
WACC8.78%
2.3 Liquidity
A Current Ratio of 6.62 indicates that CPRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.62, CPRX is in the better half of the industry, outperforming 67.61% of the companies in the same industry.
A Quick Ratio of 6.40 indicates that CPRX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.40, CPRX is doing good in the industry, outperforming 66.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 45.76% over the past year.
CPRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 34.29% yearly.
The Revenue has grown by 25.56% in the past year. This is a very strong growth!
CPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.89% yearly.
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
CPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.80% yearly.
The Revenue is expected to grow by 11.21% on average over the next years. This is quite good.
EPS Next Y19.91%
EPS Next 2Y24.48%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue Next Year19.37%
Revenue Next 2Y13.12%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.73 indicates a correct valuation of CPRX.
Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.80% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of CPRX to the average of the S&P500 Index (26.54), we can say CPRX is valued slightly cheaper.
CPRX is valuated reasonably with a Price/Forward Earnings ratio of 11.64.
Based on the Price/Forward Earnings ratio, CPRX is valued cheaper than 97.93% of the companies in the same industry.
CPRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.78, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.73 | ||
| Fwd PE | 11.64 |
4.2 Price Multiples
CPRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CPRX is cheaper than 98.12% of the companies in the same industry.
CPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CPRX is cheaper than 97.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.37 | ||
| EV/EBITDA | 7.18 |
4.3 Compensation for Growth
CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPRX may justify a higher PE ratio.
CPRX's earnings are expected to grow with 12.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.69
PEG (5Y)0.4
EPS Next 2Y24.48%
EPS Next 3Y12.53%
5. Dividend
5.1 Amount
CPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.62
+0.68 (+2.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners87.01%
Inst Owner Change1.44%
Ins Owners5.56%
Ins Owner Change-0.3%
Market Cap2.90B
Revenue(TTM)578.20M
Net Income(TTM)217.63M
Analysts88.57
Price Target35.19 (48.98%)
Short Float %7.36%
Short Ratio6.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)18.46%
EPS beat(12)11
Avg EPS beat(12)14.56%
EPS beat(16)13
Avg EPS beat(16)9.74%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)1.47%
PT rev (3m)1.47%
EPS NQ rev (1m)1.4%
EPS NQ rev (3m)7.41%
EPS NY rev (1m)5.62%
EPS NY rev (3m)5.77%
Revenue NQ rev (1m)1.33%
Revenue NQ rev (3m)3.31%
Revenue NY rev (1m)2.82%
Revenue NY rev (3m)2.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.73 | ||
| Fwd PE | 11.64 | ||
| P/S | 5.02 | ||
| P/FCF | 12.37 | ||
| P/OCF | 12.37 | ||
| P/B | 3.15 | ||
| P/tB | 3.67 | ||
| EV/EBITDA | 7.18 |
EPS(TTM)1.72
EY7.28%
EPS(NY)2.03
Fwd EY8.59%
FCF(TTM)1.91
FCFY8.08%
OCF(TTM)1.91
OCFY8.09%
SpS4.7
BVpS7.49
TBVpS6.44
PEG (NY)0.69
PEG (5Y)0.4
Graham Number17.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROCE | 28.06% | ||
| ROIC | 21.23% | ||
| ROICexc | 84.1% | ||
| ROICexgc | 187.79% | ||
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% | ||
| FCFM | 40.59% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.31% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 593.88 | ||
| Cash Conversion | 79.12% | ||
| Profit Quality | 107.83% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 15.66 |
F-Score6
WACC8.78%
ROIC/WACC2.42
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
EPS Next Y19.91%
EPS Next 2Y24.48%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
Revenue Next Year19.37%
Revenue Next 2Y13.12%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year76.08%
EBIT Next 3Y25.59%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the financial health of CATALYST PHARMACEUTICALS INC (CPRX) stock?
The financial health rating of CATALYST PHARMACEUTICALS INC (CPRX) is 8 / 10.